Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Enfortumab Vedotin

Review the clinical trials studying enfortumab vedotin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
Status: Active
Location: 20 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced and/or Node Positive Urothelial Cancer, The EV-ECLIPSE Trial
Status: Active
Location: 10 locations
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Status: Active
Location: 8 locations
Enfortumab Vedotin for the Treatment of Patients with Recurrent and/or Metastatic Adenoid Cystic Carcinoma
Status: Active
Location: 7 locations
Neoadjuvant Enfortumab Vedotin for the Treatment of Patients with High-Grade Urothelial Cancer of the Upper Urinary Tract
Status: Active
Location: 7 locations
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Status: Active
Location: 16 locations
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
Status: Active
Location: 7 locations
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer after Treatment with Chemotherapy and Immunotherapy
Status: Active
Location: 6 locations
Enfortumab Vedotin for the Treatment of Patients with Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
Status: Active
Location: 3 locations
Sacituzumab Govitecan, Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 3 locations
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 3 locations
Schedule De-Escalation of Enfortumab Vedotin Alone or With Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Status: Active
Location: 2 locations
Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with High Grade Upper Tract Urothelial Cancer who are not Candidates for, or Refuse, Nephroureterectomy
Status: Active
Location: 2 locations
Enfortumab Vedotin plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Status: Active
Location: 2 locations
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
Status: Active
Location: 3 locations
Enfortumab Vedotin for the Treatment of Patients with Unresectable or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Enfortumab Vedotin for the Treatment of Locally Advanced, Unresectable, or Metastatic Castration-Resistant Prostate Cancer, ENCORE Study
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Neoadjuvant Enfortumab Vedotin and Pembrolizumab for the Treatment of Patients with Upper Tract Urothelial Cancer, NEPTUNE Trial
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Patients with Localized Muscle-Invasive Bladder Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Pembrolizumab and Enfortumab Vedotin with Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Therapeutic Plasma Exchange with Enfortumab Vedotin and Pembrolizumab for the Treatment of Metastatic Refractory Bladder and Urinary Tract Cancers, RECIPE-B1 Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
Stereotactic Radiotherapy and Enfortumab Vedotin for the Treatment of Patients with Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Enfortumab Vedotin and Pembrolizumab Plus Radiation Therapy for the Treatment of Muscle Invasive Bladder Cancer
Status: Active
Location: University of California San Francisco, San Francisco, California
Enfortumab Vedotin with Concurrent Radiation Therapy for the Treatment of Locally Advanced Bladder Cancer, CONSOLIDATE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy and/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota